# The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC

> **NCT06243679** · — · ACTIVE_NOT_RECRUITING · sponsor: **Xiangya Hospital of Central South University** · enrollment: 100 (estimated)

## Conditions studied

- Resectable/Potentially Resectable NSCLC

## Interventions

- **DRUG:** Immunotherapy

## Key facts

- **NCT ID:** NCT06243679
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06243679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06243679, "The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06243679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*